Skip to content
15% off your first order15% off your first order

KPV 10 mg vial

Inflammation balance

Investigated for inflammatory tone and gut signaling.

$69.00CAD· $6.90/mg
1
  • Ships from Canada in 1–2 business days
  • Free shipping over $120
  • Place your order, then send the e-Transfer. We pack it as soon as it arrives.

For research use only. Not for human consumption.

Complete your setup

Needles and wipes are free. Water is $19.

About KPV

KPV is the C-terminal tripeptide fragment of alpha-MSH. Research examines its anti-inflammatory profile, particularly within the gut, and its activity independent of pigmentation signaling.

How it works

Intracellular Action
Studied for uptake into cells where it is examined for effects on NF-kB-associated inflammatory signaling.
Gut Environment
Explored in research on colonic inflammation and the signaling environment of the digestive tract.
Read the full research

What you need

  • Bacteriostatic Water
  • Needles
  • Alcohol Wipes
  • A protocol guide comes with every order

Shipping & payment

  • Packed and dispatched within 1–2 business days
  • Delivered across Canada in 2–5 business days, tracked
  • Temperature-controlled packaging where the product needs it
  • Free shipping on orders over $120
  • Prices in CAD · pay by Interac e-Transfer
Format
Lyophilised powder in a sealed vial
Strength
10 mg per vial
Storage
Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
Reconstitution
2 mL bacteriostatic water for this 10 mg vial (5 mg/mL)
Route in research
Subcutaneous
SKU
KP10

Handling

  1. 1ReconstituteAdd bacteriostatic water down the side of the vial. Swirl, never shake. Agitation damages the peptide chain.
  2. 2StoreRefrigerate at 2–8°C once mixed. Reconstituted peptide is stable for the window given in your protocol guide.
  3. 3Measure with the calculator Use an insulin syringe at the units your protocol specifies. Rotate sites and log what you take.
Purity
High-performance liquid chromatography (HPLC), by an independent laboratory
Identity
Mass spectrometry, on the same batch
How often
Every batch
COA
The certificate of analysis is matched to the lot code printed on your vial
Evidence
Preclinical

Check your lot

Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.

PreclinicalPublished KPV research consists mainly of cell culture and animal model studies, including work on skin cells, liver cells, and experimental colon inflammation, with no clinical trials identified.

What research examines

  • Colonic inflammation and gut mucosal barrier in animal models
  • NF-κB and MAPK inflammatory signaling in cell studies
  • Fine dust-induced keratinocyte inflammation and apoptosis
  • Oxidative stress regulation in cell models
  • Hepatic lipid accumulation in HepG2 cells
  • Hydrogel-based delivery systems for inflamed colon

Reported in studies

  • Human safety data are limited
  • Adverse events are not summarized in the cited cell and animal studies
  • Available evidence is preclinical and does not establish a human safety profile
  • Sold for laboratory research use only
Read the full research page· 3 cited studies

Published research protocols

500 mcg, daily, am fasted

Research protocols have used 200–500 mcg per administration, once daily (morning, fasted), in 8-week blocks with 4 weeks off.

For research use only. These figures summarize published research protocols. They are not instructions or medical advice.

Measure with the calculator

CoreX AI

Ask about KPV

Plain answers, from the basics to the studies.

Research information, not medical advice.

Often researched with KPV

Researched for recovery & repair.

Shop Recovery & repair

FAQ

Questions, answered

  • KPV is a tripeptide made of lysine, proline and valine. It is the C-terminal fragment of alpha-MSH, a naturally occurring melanocortin peptide. Research has focused on its anti-inflammatory profile, particularly in the gut, and on activity that appears independent of the pigmentation signaling associated with the parent alpha-MSH molecule. Current evidence comes largely from cell culture and animal model studies.

  • Research investigates KPV for its ability to enter cells and interfere with intracellular inflammatory signaling, rather than acting primarily at a surface receptor. Studies have examined its effects on NF-κB-associated signaling, and one keratinocyte study reported modulation of the MAPK/NF-κB pathway along with regulation of oxidative stress. A liver cell study described ROS-dependent effects on the PPARγ pathway. These mechanisms have been characterized in laboratory models.

  • The most prominent research area is colonic inflammation, including animal work in which a KPV-binding hydrogel was studied for restoring the gut mucosal barrier in an inflamed colon. Other studies have examined fine dust-induced inflammation and apoptosis in keratinocytes, and hepatic lipid accumulation in HepG2 cells. These findings are preclinical and have not been confirmed in controlled human trials.

  • Human safety data for KPV are limited. The available studies are cell culture and animal investigations, and adverse events are not summarized in these cited studies. Because the evidence base is preclinical, no established human safety profile, contraindication list, or interaction data can be described with confidence. KPV supplied by CoreX is intended for laboratory research use only.

  • Research protocols have used 200–500 mcg per administration, once daily in the morning under fasted conditions, in 8-week blocks followed by 4 weeks off, with subcutaneous administration described. These figures describe research protocols only and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.